A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps ...
Assetmark Inc. raised its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 32.9% in the 4th quarter, ...
Evercore ISI analyst Gavin Clark-Gartner maintained a Buy rating on Meiragtx Holdings (MGTX – Research Report) on March 14 and set a price ...
Check Out Our Latest Analysis on Ascendis Pharma A/S Ascendis Pharma A/S Price Performance NASDAQ:ASND opened at $138.18 on Tuesday. The stock has a market cap of $8.39 billion, a P/E ratio of -19 ...
MoonLake, a clinical-stage biopharma company developing immunology therapeutics, was created by an April 2022 merger with ...
In a report released today, Derek Archila from Wells Fargo maintained a Hold rating on Zymeworks (ZYME – Research Report), with a price target ...
European equities traded in the US as American depositary receipts were treading water late Thursday morning, edging 0.1% higher to 1,396.7 on the S&P Europe Select ADR Index. From continental Europe, ...
After hours: 7:21:52 p.m. EST Loading Chart for ASND ...